ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 3, 2015
app pub date -
Jul 25, 2013
filing date -
Jul 27, 2012
priority date (Note) -
Published
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully